Scalper1 News
Big-cap drug stocks Pharmacyclics, Valeant Pharmaceuticals and Celgene were all moving up Tuesday as the new year brought news that promised more expansion for all of them. Pharmacyclics (PCYC) vaulted 20% to 125.90 after saying a clinical trial of Imbruvica would be halted because the drug had already met its goals. The trial compared survival rates in patients with refractory chronic lymphocytic leukemia (CLL) or small lymphocytic Scalper1 News
Scalper1 News